Advanced search

Online first
Invited Review Article
Published online: 2024-08-02

open access

View PDF Download PDF file
Page views 182
Article views/downloads 145
Get Citation

Connect on Social Media

Connect on Social Media

Clinical significance of plasma candidate biomarkers of Alzheimer’s Disease

Piotr Lewczuk12, Marta Łukaszewicz-Zając3, Johannes Kornhuber1, Barbara Mroczko23
DOI: 10.5603/pjnns.100675
Pubmed: 39093167

Abstract

The number of patients with Alzheimer’s Disease (AD) has increased rapidly in recent decades. AD is a complex progressive neurodegenerative disease affecting c.14 million patients in Europe and the United States. The hallmarks of this disease are neurotic plaques composed of the amyloid-β (Aβ) peptide and neurofibrillary tangles formed of hyperphosphorylated tau protein (pTau). To date, four CSF biomarkers: amyloid beta 42 (Aβ42), Aβ42/40 ratio, Tau protein, and Tau phosphorylated at threonine 181 (pTau181) have been validated as core neurochemical AD biomarkers. Imaging biomarkers are valuable for AD diagnosis, although they suffer from limitations in their cost and accessibility, while CSF biomarkers require lumbar puncture. Thus, there is an urgent need for alternative, less invasive and more cost-effective biomarkers capable of diagnosing and monitoring AD progression in a clinical context, as well as expediting the development of new therapeutic strategies. This review assesses the potential clinical significance of plasma candidate biomarkers in AD diagnosis. We conclude that these proteins might hold great promise in identifying the pathological features of AD. However, the future implementation process, and validation of the assays’ accuracy using predefined cut-offs across more diverse patient populations, are crucial in establishing their utility in daily practice.

Keywords: Alzheimer’s Diseaseamyloid betatauplasma biomarkers

Article available in PDF format

View PDF Download PDF file

References

  1. World Health Organization, Dementia. https://www.who.int/news-room/fact-sheets/detail/dementia (18 Aug 2021).
  2. Feigin VL, Vos T, Nichols E, et al. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol. 2020; 19(3): 255–265.
    CrossRefPubMed
  3. Rocca WA, Petersen RC, Knopman DS, et al. Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimers Dement. 2011; 7(1): 80–93.
    CrossRefPubMed
  4. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011; 7(3): 137–152.
    CrossRefPubMed
  5. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007; 6(8): 734–746.
    CrossRefPubMed
  6. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010; 74(3): 201–209.
    CrossRefPubMed
  7. Hansson O, Lehmann S, Otto M, et al. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease. Alzheimers Res Ther. 2019; 11(1): 34.
    CrossRefPubMed
  8. Lewczuk P, Riederer P, O'Bryant SE, et al. Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry. 2018; 19(4): 244–328.
    CrossRefPubMed
  9. Carroll CM, Li YM. Physiological and pathological roles of the γ-secretase complex. Brain Res Bull. 2016; 126(Pt 2): 199–206.
    CrossRefPubMed
  10. Portelius E, Price E, Brinkmalm G, et al. A novel pathway for amyloid precursor protein processing. Neurobiol Aging. 2011; 32(6): 1090–1098.
    CrossRefPubMed
  11. Lewczuk P, Matzen A, Blennow K, et al. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease. J Alzheimers Dis. 2017; 55(2): 813–822.
    CrossRefPubMed
  12. Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15(7): 673–684.
    CrossRefPubMed
  13. Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF. Neurology. 1999; 52(8): 1555–1555.
    CrossRef
  14. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998; 55(7): 937–945.
    CrossRefPubMed
  15. Lewczuk P, Esselmann H, Bibl M, et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature. J Mol Neurosci. 2004; 23(1-2): 115–122.
    CrossRefPubMed
  16. Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med. 2018; 284(6): 643–663.
    CrossRefPubMed
  17. Lewczuk P, Esselmann H, Otto M, et al. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging. 2004; 25(3): 273–281.
    CrossRefPubMed
  18. Wiltfang J, Esselmann H, Bibl M, et al. Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho‐Tau in patients with low‐ and high‐CSF Aβ40 load. Journal of Neurochemistry. 2006; 101(4): 1053–1059.
    CrossRef
  19. Lewczuk P, Wiltfang J, Kornhuber J, et al. Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory. Diagnostics (Basel). 2021; 11(12).
    CrossRefPubMed
  20. Palmqvist S, Zetterberg H, Blennow K, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014; 71(10): 1282–1289.
    CrossRefPubMed
  21. Palmqvist S, Zetterberg H, Mattsson N, et al. Alzheimer's Disease Neuroimaging Initiative, Swedish BioFINDER Study Group. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology. 2015; 85(14): 1240–1249.
    CrossRefPubMed
  22. Palmqvist S, Mattsson N, Hansson O, et al. Alzheimer’s Disease Neuroimaging Initiative. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain. 2016; 139(Pt 4): 1226–1236.
    CrossRefPubMed
  23. Lewczuk P, Kornhuber J. Do we still need positron emission tomography for early Alzheimer's disease diagnosis? Brain. 2016; 139(11): e60.
    CrossRefPubMed
  24. Henjum K, Almdahl IS, Årskog V, et al. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. Alzheimers Res Ther. 2016; 8(1): 17.
    CrossRefPubMed
  25. Mattsson N, Insel PS, Palmqvist S, et al. Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis. Nat Commun. 2016; 7: 10918.
    CrossRefPubMed
  26. Janelidze S, Zetterberg H, Mattsson N, et al. Swedish BioFINDER study group. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016; 3(3): 154–165.
    CrossRefPubMed
  27. Mulugeta E, Londos E, Ballard C, et al. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2011; 82(2): 160–164.
    CrossRefPubMed
  28. Lista S, Toschi N, Baldacci F, et al. Alzheimer Precision Medicine Initiative (APMI). Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. J Alzheimers Dis. 2017; 59(4): 1327–1334.
    CrossRefPubMed
  29. Herskovits AZ, Locascio JJ, Peskind ER, et al. A Luminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid. PLoS One. 2013; 8(7): e67898.
    CrossRefPubMed
  30. Fukumoto H, Tokuda T, Kasai T, et al. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 2010; 24(8): 2716–2726.
    CrossRefPubMed
  31. Gao CM, Yam AY, Wang X, et al. Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. PLoS One. 2010; 5(12): e15725.
    CrossRefPubMed
  32. Mandelkow E, von Bergen M, Biernat J, et al. Structural principles of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol. 2007; 17(1): 83–90.
    CrossRefPubMed
  33. Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003; 289(16): 2094–2103.
    CrossRefPubMed
  34. Kohnken R, Buerger K, Zinkowski R, et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett. 2000; 287(3): 187–190.
    CrossRefPubMed
  35. Hampel H, Buerger K, Zinkowski R, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry. 2004; 61(1): 95–102.
    CrossRefPubMed
  36. Parnetti L, Lanari A, Amici S, et al. Phospho-Tau International Study Group. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci. 2001; 22(1): 77–78.
    CrossRefPubMed
  37. Arai H, Ishiguro K, Ohno H, et al. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol. 2000; 166(1): 201–203.
    CrossRefPubMed
  38. Suárez-Calvet M, Karikari TK, Ashton NJ, et al. ALFA Study. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected. EMBO Mol Med. 2020; 12(12): e12921.
    CrossRefPubMed
  39. Leuzy A, Janelidze S, Mattsson-Carlgren N, et al. Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. Neurology. 2021; 97(17): e1681–e1694.
    CrossRefPubMed
  40. Buchhave P, Minthon L, Zetterberg H, et al. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012; 69(1): 98–106.
    CrossRefPubMed
  41. de Leon MJ, Pirraglia E, Osorio RS, et al. Alzheimer’s Disease Neuroimaging Initiative, National Alzheimer’s Coordinating Center. The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer's disease. PLoS One. 2018; 13(2): e0191240.
    CrossRefPubMed
  42. Molinuevo JL, Ayton S, Batrla R, et al. Current state of Alzheimer's fluid biomarkers. Acta Neuropathol. 2018; 136(6): 821–853.
    CrossRefPubMed
  43. Shen Y, Wang H, Sun Q, et al. Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment. Biol Psychiatry. 2018; 83(5): 447–455.
    CrossRefPubMed
  44. Leung YY, Toledo JB, Nefedov A, et al. Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. Alzheimers Dement (Amst). 2015; 1(3): 339–348.
    CrossRefPubMed
  45. Guo LH, Alexopoulos P, Perneczky R. Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 2013; 263(7): 553–560.
    CrossRefPubMed
  46. Heslegrave A, Heywood W, Paterson R, et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol Neurodegener. 2016; 11: 3.
    CrossRefPubMed
  47. Baldacci F, Lista S, Cavedo E, et al. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. Expert Rev Proteomics. 2017; 14(4): 285–299.
    CrossRefPubMed
  48. Muszyński P, Kulczyńska-Przybik A, Borawska R, et al. The Relationship between Markers of Inflammation and Degeneration in the Central Nervous System and the Blood-Brain Barrier Impairment in Alzheimer's Disease. J Alzheimers Dis. 2017; 59(3): 903–912.
    CrossRefPubMed
  49. Iturria-Medina Y, Sotero RC, Toussaint PJ, et al. Alzheimer’s Disease Neuroimaging Initiative. Early role of vascular dysregulation on late-onsheimer’s disease based on multifactorial data-driven analysis. Nat Commun. 2016; 7: 11934.
  50. Pereira JB, Westman E, Hansson O. Alzheimer’s Disease Neuroimaging Initiative. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer’s disease. Neurobiol Aging. 2017; 58: 14–29.
  51. Öhrfelt A, Brinkmalm A, Dumurgier J, et al. The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. Alzheimers Res Ther. 2016; 8(1): 41.
    CrossRefPubMed
  52. Chiasserini D, Biscetti L, Eusebi P, et al. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. Alzheimers Res Ther. 2017; 9(1): 52.
    CrossRefPubMed
  53. Feneberg E, Steinacker P, Lehnert S, et al. Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15(5-6): 351–356.
    CrossRefPubMed
  54. Mroczko B, Groblewska M, Zboch M, et al. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease. J Alzheimers Dis. 2015; 43(3): 1031–1037.
    CrossRefPubMed
  55. Zetterberg H, Skillbäck T, Mattsson N, et al. Alzheimer’s Disease Neuroimaging Initiative. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurol. 2016; 73(1): 60–67.
    CrossRefPubMed
  56. Mroczko B, Groblewska M, Zboch M, et al. Concentrations of matrix metalloproteinases and their tissue inhibitors in the cerebrospinal fluid of patients with Alzheimer's disease. J Alzheimers Dis. 2014; 40(2): 351–357.
    CrossRefPubMed
  57. Rohrer JD, Woollacott IOC, Dick KM, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016; 87(13): 1329–1336.
    CrossRefPubMed
  58. Barage SH, Sonawane KD. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides. 2015; 52: 1–18.
    CrossRefPubMed
  59. Morris GP, Clark IA, Vissel B. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun. 2014; 2: 135.
    CrossRefPubMed
  60. Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer's disease. Trends Mol Med. 2015; 21(6): 394–402.
    CrossRefPubMed
  61. Lewczuk P, Lelental N, Lachmann I, et al. Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. J Alzheimers Dis. 2017; 55(1): 159–170.
    CrossRefPubMed
  62. Ermann N, Lewczuk P, Schmitz M, et al. CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD. Ann Clin Transl Neurol. 2018; 5(7): 883–887.
    CrossRefPubMed
  63. Foiani MS, Cicognola C, Ermann N, et al. Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. J Neurol Neurosurg Psychiatry. 2019; 90(7): 740–746.
    CrossRefPubMed
  64. Parnetti L, Cicognola C, Eusebi P, et al. Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis. Biomark Med. 2016; 10(1): 35–49.
    CrossRefPubMed
  65. Eusebi P, Giannandrea D, Biscetti L, et al. Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis. BMJ Open. 2016; 6(6): e011113.
    CrossRefPubMed
  66. Twohig D, Nielsen HM. α-synuclein in the pathophysiology of Alzheimer's disease. Mol Neurodegener. 2019; 14(1): 23.
    CrossRefPubMed
  67. Slaets S, Vanmechelen E, Le Bastard N, et al. Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels. Alzheimers Dement. 2014; 10(5 Suppl): S290–S298.
    CrossRefPubMed
  68. Engelborghs S, Niemantsverdriet E, Struyfs H, et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst). 2017; 8: 111–126.
    CrossRefPubMed
  69. Hansson O, Mikulskis A, Fagan AM, et al. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. Alzheimers Dement. 2018; 14(10): 1313–1333.
    CrossRefPubMed
  70. Bjerke M, Andreasson U, Kuhlmann J, et al. Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements. Clin Chem Lab Med. 2016; 54(7): 1177–1191.
    CrossRefPubMed
  71. Lewczuk P, Zimmermann R, Wiltfang J, et al. Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers. J Neural Transm (Vienna). 2009; 116(9): 1163–1167.
    CrossRefPubMed
  72. Lehmann S, Delaby C, Boursier G, et al. Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLM Scale. Front Aging Neurosci. 2018; 10: 138.
    CrossRefPubMed
  73. Jack CR, Bennett DA, Blennow K, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016; 87(5): 539–547.
    CrossRefPubMed
  74. Lewczuk P, Kornhuber J, Toledo JB, et al. German Dementia Competence Network, US-ADNI. Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. J Alzheimers Dis. 2015; 48(2): 433–441.
    CrossRefPubMed
  75. Baldeiras I, Santana I, Leitão MJ, et al. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease. Alzheimers Res Ther. 2019; 11(1): 2.
    CrossRefPubMed
  76. Skillbäck T, Kornhuber J, Blennow K, et al. Alzheimer’s Disease Neuroimaging Initiative. Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease. J Alzheimers Dis. 2019; 69(2): 551–559.
    CrossRefPubMed
  77. Somers C, Lewczuk P, Sieben A, et al. Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects. J Alzheimers Dis. 2019; 68(3): 1151–1159.
    CrossRefPubMed
  78. Janelidze S, Berron D, Smith R, et al. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurol. 2021; 78(2): 149–156.
    CrossRefPubMed
  79. Beach TG, Monsell SE, Phillips LE, et al. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012; 71(4): 266–273.
    CrossRefPubMed
  80. Jack CR, Bennett DA, Blennow K, et al. Contributors. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4): 535–562.
    CrossRefPubMed
  81. Palmqvist S, Stomrud E, Cullen N, et al. An accurate fully automated panel of plasma biomarkers for Alzheimer's disease. Alzheimers Dement. 2023; 19(4): 1204–1215.
    CrossRefPubMed
  82. Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol. 2021; 20(6): 484–496.
    CrossRefPubMed
  83. Rabinovici GD, Carrillo MC, Apgar C, et al. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA. 2019; 321(13): 1286–1294.
    CrossRefPubMed
  84. Brand AL, Lawler PE, Bollinger JG, et al. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review. Alzheimers Res Ther. 2022; 14(1): 195.
    CrossRefPubMed
  85. Bateman RJ, Munsell LY, Morris JC, et al. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006; 12(7): 856–861.
    CrossRefPubMed
  86. Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021; 27(6): 954–963.
    CrossRefPubMed
  87. Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017; 13(8): 841–849.
    CrossRefPubMed
  88. Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol. 2022; 21(1): 66–77.
    CrossRefPubMed
  89. O'Bryant SE, Mielke MM, Rissman RA, et al. Biofluid Based Biomarker Professional Interest Area. Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement. 2017; 13(1): 45–58.
    CrossRefPubMed
  90. Pannee J, Törnqvist U, Westerlund A, et al. The amyloid-β degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease. Neurosci Lett. 2014; 573: 7–12.
    CrossRefPubMed
  91. Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019; 93(17): e1647–e1659.
    CrossRefPubMed
  92. Pérez-Grijalba V, Arbizu J, Romero J, et al. AB255 Study Group. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study. Alzheimers Res Ther. 2019; 11(1): 96.
    CrossRefPubMed
  93. Tanaka T, Ruifen JC, Nai YH, et al. Head-to-head comparison of amplified plasmonic exosome Aβ42 platform and single-molecule array immunoassay in a memory clinic cohort. Eur J Neurol. 2021; 28(5): 1479–1489.
    CrossRefPubMed
  94. Smirnov DS, Ashton NJ, Blennow K, et al. Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change. Acta Neuropathol. 2022; 143(4): 487–503.
    CrossRefPubMed
  95. Keshavan A, Pannee J, Karikari T, et al. Population-based blood screening for pre-clinical Alzheimer’s disease: a British birth cohort at age 70. Brain. 2021; 144(2): 434–449.
    CrossRefPubMed
  96. Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-β biomarkers for Alzheimer's disease. Nature. 2018; 554(7691): 249–254.
    CrossRefPubMed
  97. West T, Kirmess KM, Meyer MR, et al. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Mol Neurodegener. 2021; 16(1): 30.
    CrossRefPubMed
  98. Janelidze S, Stomrud E, Palmqvist S, et al. Plasma β-amyloid in Alzheimer's disease and vascular disease. Sci Rep. 2016; 6: 26801.
    CrossRefPubMed
  99. Hansson O, Zetterberg H, Vanmechelen E, et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment. Neurobiol Aging. 2010; 31: 357–67.
  100. Kuo YM, Emmerling MR, Lampert HC, et al. High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun. 1999; 257(3): 787–791.
    CrossRefPubMed
  101. Mattsson N, Schöll M, Strandberg O, et al. 18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease. EMBO Molecular Medicine. 2017; 9(9): 1212–1223.
    CrossRef
  102. Mattsson-Carlgren N, Andersson E, Janelidze S, et al. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. Sci Adv. 2020; 6(16): eaaz2387.
    CrossRefPubMed
  103. Meyer PF, Pichet Binette A, Gonneaud J, et al. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography. JAMA Neurol. 2020; 77(4): 508–516.
    CrossRefPubMed
  104. Bejanin A, Schonhaut DR, La Joie R, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. Brain. 2017; 140(12): 3286–3300.
    CrossRefPubMed
  105. Ossenkoppele R, Smith R, Ohlsson T, et al. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019; 92(6).
    CrossRef
  106. Mattsson N, Zetterberg H, Janelidze S, et al. ADNI Investigators. Plasma tau in Alzheimer disease. Neurology. 2016; 87(17): 1827–1835.
    CrossRefPubMed
  107. Mielke MM, Hagen CE, Xu J, et al. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018; 14(8): 989–997.
    CrossRefPubMed
  108. Tatebe H, Kasai T, Ohmichi T, et al. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome. Mol Neurodegener. 2017; 12(1): 63.
    CrossRefPubMed
  109. Yang CC, Chiu MJ, Chen TF, et al. Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease. J Alzheimers Dis. 2018; 61(4): 1323–1332.
    CrossRefPubMed
  110. Coomans EM, Verberk IMW, Ossenkoppele R, et al. A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer's Disease Continuum. J Nucl Med. 2023; 64(3): 437–443.
    CrossRefPubMed
  111. Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med. 2020; 26(3): 379–386.
    CrossRefPubMed
  112. Barthélemy NR, Bateman RJ, Hirtz C, et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. Alzheimers Res Ther. 2020; 12(1): 26.
    CrossRefPubMed
  113. Janelidze S, Stomrud E, Smith R, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. Nat Commun. 2020; 11(1): 1683.
    CrossRefPubMed
  114. Palmqvist S, Insel PS, Stomrud E, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Mol Med. 2019; 11(12): e11170.
    CrossRefPubMed
  115. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2020; 324(8): 772–781.
    CrossRefPubMed
  116. Janelidze S, Bali D, Ashton NJ, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease. Brain. 2023; 146(4): 1592–1601.
    CrossRefPubMed
  117. Palmqvist S, Tideman P, Cullen N, et al. Alzheimer’s Disease Neuroimaging Initiative. Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021; 27(6): 1034–1042.
    CrossRefPubMed
  118. Ashton NJ, Pascoal TA, Karikari TK, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta Neuropathol. 2021; 141(5): 709–724.
    CrossRefPubMed
  119. Brickman AM, Manly JJ, Honig LS, et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. 2021; 17(8): 1353–1364.
    CrossRefPubMed
  120. Karikari TK, Emeršič A, Vrillon A, et al. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. Alzheimers Dement. 2021; 17(5): 755–767.
    CrossRefPubMed
  121. Thijssen EH, La Joie R, Strom A, et al. Advancing Research and Treatment for Frontotemporal Lobar Degeneration investigators. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021; 20(9): 739–752.
    CrossRefPubMed
  122. Chatterjee P, Pedrini S, Stoops E, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease. Translational Psychiatry. 2021; 11(1).
    CrossRef
  123. Chatterjee P, Pedrini S, Doecke JD, et al. AIBL Research Group. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement. 2023; 19(4): 1117–1134.
    CrossRefPubMed
  124. Brum WS, Cullen NC, Therriault J, et al. A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings. Nat Commun. 2024; 15(1): 2311.
    CrossRefPubMed
  125. Saitgareeva A, Bulygin K, Gareev I, et al. The role of microglia in the development of neurodegeneration. Neurological Sciences. 2020; 41(12): 3609–3615.
    CrossRef
  126. Heneka M, Carson M, Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015; 14(4): 388–405.
    CrossRef
  127. Prins S, de Kam ML, Teunissen CE, et al. Inflammatory plasma biomarkers in subjects with preclinical Alzheimer's disease. Alzheimers Res Ther. 2022; 14(1): 106.
    CrossRefPubMed
  128. Vergallo A, Lista S, Lemercier P, et al. INSIGHT-preAD study group and the Alzheimer Precision Medicine Initiative (APMI), INSIGHT-preAD study group, Alzheimer Precision Medicine Initiative (APMI). Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers. Neurobiol Aging. 2020; 96: 22–32.
    CrossRefPubMed
  129. Kronborg G, Ostergaard C, Weis N, et al. Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease. Scand J Infect Dis. 2002; 34(5): 323–326.
    CrossRefPubMed
  130. Verberk IMW, Laarhuis MB, van den Bosch KA, et al. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Lancet Healthy Longev. 2021; 2(2): e87–e95.
    CrossRefPubMed
  131. Prins S, Zhuparris A, Hart EP, et al. A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation. Alzheimers Res Ther. 2021; 13(1): 132.
    CrossRefPubMed
  132. Pereira J, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease. Brain. 2021; 144(11): 3505–3516.
    CrossRef
  133. Bettcher BM, Fitch R, Wynn MJ, et al. MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes. Alzheimers Dement (Amst). 2016; 3: 91–97.
    CrossRefPubMed
  134. Morgan AR, Touchard S, Leckey C, et al. NIMA Consortium, Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease. Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimers Dement. 2019; 15(6): 776–787.
    CrossRefPubMed
  135. Hu Q, Shi M, Li Y, et al. Elevated plasma neurofilament light was associated with multi-modal neuroimaging features in Alzheimer's Disease signature regions and predicted future tau deposition. Res Sq. 2024.
    CrossRefPubMed
  136. Yuan A, Rao M, Nixon R. Neurofilaments and Neurofilament Proteins in Health and Disease. Cold Spring Harbor Perspectives in Biology. 2017; 9(4): a018309.
    CrossRef
  137. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Research. 2003; 987(1): 25–31.
    CrossRef
  138. Preische O, Schultz SA, Apel A, et al. Dominantly Inherited Alzheimer Network. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019; 25(2): 277–283.
    CrossRefPubMed
  139. Mattsson N, Andreasson U, Zetterberg H, et al. Alzheimer’s Disease Neuroimaging Initiative. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2017; 74(5): 557–566.
    CrossRefPubMed
  140. Mattsson N, Cullen NC, Andreasson U, et al. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2019; 76(7): 791–799.
    CrossRefPubMed
  141. Benedet A, Leuzy A, Pascoal T, et al. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer’s disease. Brain. 2020; 143(12): 3793–3804.
    CrossRef
  142. Nabizadeh F, Balabandian M, Rostami MR, et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI). Plasma neurofilament light levels correlate with white matter damage prior to Alzheimer's disease: results from ADNI. Aging Clin Exp Res. 2022; 34(10): 2363–2372.
    CrossRefPubMed
  143. Lewczuk P, Ermann N, Andreasson U, et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. Alzheimers Res Ther. 2018; 10(1): 71.
    CrossRefPubMed
  144. Clark C, Lewczuk P, Kornhuber J, et al. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression. Alzheimers Res Ther. 2021; 13(1): 65.
    CrossRefPubMed
  145. Chatterjee P, Pedrini S, Ashton NJ, et al. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimers Dement. 2022; 18(6): 1141–1154.
    CrossRefPubMed
  146. Gisslén M, Price RW, Andreasson U, et al. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine. 2016; 3: 135–140.
    CrossRefPubMed
  147. Weston PSJ, Poole T, Ryan NS, et al. Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology. 2017; 89(21): 2167–2175.
    CrossRefPubMed
  148. Blennow K, Zetterberg H. Understanding biomarkers of neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding. Nat Med. 2015; 21(3): 217–219.
    CrossRefPubMed
  149. Guo T, Shaw LM, Trojanowski JQ, et al. Alzheimer's Disease Neuroimaging Initiative. Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults. Neurology. 2020; 95(15): e2075–e2085.
    CrossRefPubMed
  150. Luo J, Agboola F, Grant E, et al. Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study. Neurology. 2020; 95(23): e3104–e3116.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice